Orchard Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
A live webcast of the presentation will be available under "News & Events" in the Investors & Media section of the company's website at orchard-tx.com. A replay of the webcast will be archived on the Orchard website following the presentation.
Orchard’s portfolio of ex vivo, autologous, hematopoietic stem cell (HSC) based gene therapies includes Strimvelis®, a gammaretroviral vector-based gene therapy and the first such treatment approved by the
Orchard currently has offices in the
Director, Investor Relations
Manager, Corporate Communications
Source: Orchard Therapeutics (Europe) Limited